{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:00:36Z","timestamp":1794744036241,"version":"4.9.1"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41581-026-01066-0","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T08:01:43Z","timestamp":1774425703000},"page":"474-486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Insulin resistance and hyperinsulinaemia in kidney disease: mechanisms and metabolic effects"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4979-3799","authenticated-orcid":false,"given":"Hussein","family":"Zaitoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Abdul-Ghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3839-1724","authenticated-orcid":false,"given":"Ralph A.","family":"DeFronzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"1066_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","volume":"207","author":"A Francis","year":"2024","unstructured":"Francis, A. et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat. Rev. Nephrol. 207, 473\u2013485 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"1066_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.22.2440","volume":"168","author":"LD Bash","year":"2008","unstructured":"Bash, L. D., Selvin, E., Steffes, M., Coresh, J. & Astor, B. C. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: the Atherosclerosis Risk In Communities (ARIC) study. Arch. Intern. Med. 168, 2440 (2008).","journal-title":"Arch. Intern. Med."},{"key":"1066_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2337\/diab.37.6.667","volume":"37","author":"RA DeFronzo","year":"1988","unstructured":"DeFronzo, R. A. The triumvirate: \u03b2-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37, 667\u2013687 (1988).","journal-title":"Diabetes"},{"key":"1066_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S0025-6196(12)64818-6","volume":"61","author":"JE GERICH","year":"1986","unstructured":"GERICH, J. E. Insulin-dependent diabetes mellitus: pathophysiology. Mayo Clin. Proc. 61, 787\u2013791 (1986).","journal-title":"Mayo Clin. Proc."},{"key":"1066_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1146\/annurev-physiol-031622-043133","volume":"85","author":"SM Najjar","year":"2023","unstructured":"Najjar, S. M., Caprio, S. & Gastaldelli, A. Insulin clearance in health and disease. Annu. Rev. Physiol. 85, 363\u2013381 (2023).","journal-title":"Annu. Rev. Physiol."},{"key":"1066_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.kint.2015.11.007","volume":"89","author":"R Nielsen","year":"2016","unstructured":"Nielsen, R., Christensen, E. I. & Birn, H. Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease. Kidney Int. 89, 58\u201367 (2016).","journal-title":"Kidney Int."},{"key":"1066_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101255","volume":"52","author":"MC Lawrence","year":"2021","unstructured":"Lawrence, M. C. Understanding insulin and its receptor from their three-dimensional structures. Mol. Metab. 52, 101255 (2021).","journal-title":"Mol. Metab."},{"key":"1066_CR8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/MNH.0b013e32835abb52","volume":"22","author":"LJ Hale","year":"2013","unstructured":"Hale, L. J. & Coward, R. J. M. The insulin receptor and the kidney. Curr. Opin. Nephrol. Hypertens. 22, 100\u2013106 (2013).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"1066_CR9","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00125-018-4656-5","volume":"61","author":"C Ghezzi","year":"2018","unstructured":"Ghezzi, C., Loo, D. D. F. & Wright, E. M. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia 61, 2087\u20132097 (2018).","journal-title":"Diabetologia"},{"key":"1066_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cmet.2010.08.015","volume":"12","author":"GI Welsh","year":"2010","unstructured":"Welsh, G. I. et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab. 12, 329\u2013340 (2010).","journal-title":"Cell Metab."},{"key":"1066_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/BF00252649","volume":"21","author":"RA DeFronzo","year":"1981","unstructured":"DeFronzo, R. A. The effect of insulin on renal sodium metabolism \u2014 a review with clinical implications. Diabetologia 21, 165\u2013171 (1981).","journal-title":"Diabetologia"},{"key":"1066_CR12","doi-asserted-by":"publisher","first-page":"8134","DOI":"10.1002\/jcp.27598","volume":"234","author":"MT Swe","year":"2019","unstructured":"Swe, M. T., Pongchaidecha, A., Chatsudthipong, V., Chattipakorn, N. & Lungkaphin, A. Molecular signaling mechanisms of renal gluconeogenesis in nondiabetic and diabetic conditions. J. Cell. Physiol. 234, 8134\u20138151 (2019).","journal-title":"J. Cell. Physiol."},{"key":"1066_CR13","doi-asserted-by":"publisher","first-page":"109005","DOI":"10.1016\/j.abb.2021.109005","volume":"710","author":"D Rogacka","year":"2021","unstructured":"Rogacka, D. Insulin resistance in glomerular podocytes: potential mechanisms of induction. Arch. Biochem. Biophys. 710, 109005 (2021).","journal-title":"Arch. Biochem. Biophys."},{"key":"1066_CR14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/MNH.0b013e32832f7002","volume":"18","author":"A Jauregui","year":"2009","unstructured":"Jauregui, A., Mintz, D. H., Mundel, P. & Fornon, A. Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria. Curr. Opin. Nephrol. Hypertens. 18, 539\u2013545 (2009).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"1066_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5825170","volume":"2016","author":"S Horita","year":"2016","unstructured":"Horita, S. et al. Selective insulin resistance in the kidney. Biomed. Res. Int. 2016, 5825170 (2016).","journal-title":"Biomed. Res. Int."},{"key":"1066_CR16","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/BF00400466","volume":"37","author":"S Del Prato","year":"1994","unstructured":"Del Prato, S. et al. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia 37, 1025\u20131035 (1994).","journal-title":"Diabetologia"},{"key":"1066_CR17","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000093632","volume":"26","author":"PA Sarafidis","year":"2006","unstructured":"Sarafidis, P. A. & Ruilope, L. M. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am. J. Nephrol. 26, 232\u2013244 (2006).","journal-title":"Am. J. Nephrol."},{"key":"1066_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1046\/j.1440-1797.2000.00008.x","volume":"5","author":"N Yano","year":"2000","unstructured":"Yano, N. et al. Genomic repertoire of human mesangial cells: comprehensive analysis of gene expression by cDNA array hybridization. Nephrology 5, 215\u2013223 (2000).","journal-title":"Nephrology"},{"key":"1066_CR19","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/10739680701283018","volume":"14","author":"SF Knight","year":"2007","unstructured":"Knight, S. F. & Imig, J. D. Obesity, insulin resistance, and renal function. Microcirculation 14, 349\u2013362 (2007).","journal-title":"Microcirculation"},{"key":"1066_CR20","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1172\/JCI116815","volume":"92","author":"BN Ling","year":"1993","unstructured":"Ling, B. N., Seal, E. E. & Eaton, D. C. Regulation of mesangial cell ion channels by insulin and angiotensin II. Possible role in diabetic glomerular hyperfiltration. J. Clin. Invest. 92, 2141\u20132151 (1993).","journal-title":"J. Clin. Invest."},{"key":"1066_CR21","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/01.CIR.101.6.676","volume":"101","author":"K Kuboki","year":"2000","unstructured":"Kuboki, K. et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo \u2014 a specific vascular action of insulin. Circulation 101, 676\u2013681 (2000).","journal-title":"Circulation"},{"key":"1066_CR22","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.2337\/diabetes.54.11.3095","volume":"54","author":"RJM Coward","year":"2005","unstructured":"Coward, R. J. M. et al. The human glomerular podocyte is a novel target for insulin action. Diabetes 54, 3095\u20133102 (2005).","journal-title":"Diabetes"},{"key":"1066_CR23","doi-asserted-by":"publisher","first-page":"382","DOI":"10.2337\/diacare.24.2.382","volume":"24","author":"JE Gerich","year":"2001","unstructured":"Gerich, J. E., Woerle, H. J., Meyer, C. & Stumvoll, M. Renal gluconeogenesisIts importance in human glucose homeostasis. Diabetes Care 24, 382\u2013391 (2001).","journal-title":"Diabetes Care"},{"key":"1066_CR24","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/ckj\/sfad046","volume":"16","author":"D Dalga","year":"2023","unstructured":"Dalga, D., Verissimo, T. & de Seigneux, S. Gluconeogenesis in the kidney: in health and in chronic kidney disease. Clin. Kidney J. 16, 1249 (2023).","journal-title":"Clin. Kidney J."},{"key":"1066_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3389\/fcell.2020.00519","volume":"8","author":"AF Pina","year":"2020","unstructured":"Pina, A. F. et al. Insulin: trigger and target of renal functions. Front. Cell Dev. Biol. 8, 519 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"1066_CR26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/BF00405088","volume":"34","author":"P Sk\u00f8tt","year":"1991","unstructured":"Sk\u00f8tt, P. et al. Effect of insulin on renal sodium handling in hyperinsulinaemic type 2 (non-insulin-dependent) diabetic patients with peripheral insulin resistance. Diabetologia 34, 275\u2013281 (1991).","journal-title":"Diabetologia"},{"key":"1066_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/BF00586561","volume":"323","author":"A Nizet","year":"1971","unstructured":"Nizet, A., Lefebvre, P. & Crabb\u00e9, J. Control by insulin of sodium potassium and water excretion by the isolated dog kidney. Pfl\u00fcgers Arch. 323, 11\u201320 (1971).","journal-title":"Pfl\u00fcgers Arch."},{"key":"1066_CR28","doi-asserted-by":"publisher","first-page":"F712","DOI":"10.1152\/ajprenal.00264.2020","volume":"319","author":"A Onishi","year":"2020","unstructured":"Onishi, A. et al. A role for tubular Na+\/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin. Am. J. Physiol. Renal Physiol. 319, F712\u2013F728 (2020).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1066_CR29","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/ki.2014.351","volume":"87","author":"M Nakamura","year":"2015","unstructured":"Nakamura, M. et al. Preserved Na\/HCO3 cotransporter sensitivity to insulin may promote hypertension in metabolic syndrome. Kidney Int. 87, 535\u2013542 (2015).","journal-title":"Kidney Int."},{"key":"1066_CR30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/HJH.0b013e32835bbb83","volume":"31","author":"M Ch\u00e1vez-Canales","year":"2013","unstructured":"Ch\u00e1vez-Canales, M. et al. Insulin increases the functional activity of the renal NaCl cotransporter. J. Hypertens. 31, 303\u2013311 (2013).","journal-title":"J. Hypertens."},{"key":"1066_CR31","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1093\/ndt\/14.10.2357","volume":"14","author":"JC Ter Maaten","year":"1999","unstructured":"Ter Maaten, J. C. et al. Insulin\u2019s acute effects on glomerular filtration rate correlate with insulin sensitivity whereas insulin\u2019s acute effects on proximal tubular sodium reabsorption correlation with salt sensitivity in normal subjects. Nephrol. Dial. Transpl. 14, 2357\u20132363 (1999).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1066_CR32","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/nyas.12395","volume":"1311","author":"C Manrique","year":"2014","unstructured":"Manrique, C., Lastra, G. & Sowers, J. R. New insights into insulin action and resistance in the vasculature. Ann. N. Y. Acad. Sci. 1311, 138\u2013150 (2014).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1066_CR33","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.2527\/jas.2011-4129","volume":"90","author":"I Tebot","year":"2012","unstructured":"Tebot, I. et al. The effect of intravenous insulin infusion on renal blood flow in conscious sheep is partially mediated by nitric oxide but not by prostaglandins. J. Anim. Sci. 90, 1192\u20131200 (2012).","journal-title":"J. Anim. Sci."},{"key":"1066_CR34","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1042\/BCJ20210071","volume":"478","author":"P Ferr\u00e9","year":"2021","unstructured":"Ferr\u00e9, P., Phan, F. & Foufelle, F. SREBP-1c and lipogenesis in the liver: an update. Biochem. J. 478, 3723\u20133739 (2021).","journal-title":"Biochem. J."},{"key":"1066_CR35","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.3390\/nu13051580","volume":"13","author":"LS Gewin","year":"2021","unstructured":"Gewin, L. S. Sugar or fat? Renal tubular metabolism reviewed in health and disease. Nutrients 13, 1580 (2021).","journal-title":"Nutrients"},{"key":"1066_CR36","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1194\/jlr.P040501","volume":"55","author":"M Herman-Edelstein","year":"2014","unstructured":"Herman-Edelstein, M., Scherzer, P., Tobar, A., Levi, M. & Gafter, U. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J. Lipid Res. 55, 561\u2013572 (2014).","journal-title":"J. Lipid Res."},{"key":"1066_CR37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172963","volume":"134","author":"D Mukhi","year":"2024","unstructured":"Mukhi, D. et al. ACSS2 gene variants determine kidney disease risk by controlling de novo lipogenesis in kidney tubules. J. Clin. Invest. 134, e172963 (2024).","journal-title":"J. Clin. Invest."},{"key":"1066_CR38","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/2091244a0","volume":"209","author":"H Nieth","year":"1966","unstructured":"Nieth, H. & Schollmeyer, P. Substrate-utilization of the human kidney. Nature 209, 1244\u20131245 (1966).","journal-title":"Nature"},{"key":"1066_CR39","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1681\/ASN.2007010089","volume":"18","author":"S Kume","year":"2007","unstructured":"Kume, S. et al. Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. J. Am. Soc. Nephrol. 18, 2715\u20132723 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1066_CR40","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.kint.2024.02.025","volume":"106","author":"LE Lee","year":"2024","unstructured":"Lee, L. E., Doke, T., Mukhi, D. & Susztak, K. The key role of altered tubule cell lipid metabolism in kidney disease development. Kidney Int. 106, 24\u201334 (2024).","journal-title":"Kidney Int."},{"key":"1066_CR41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1146\/annurev.ph.47.030185.000505","volume":"47","author":"LJ Mandel","year":"1985","unstructured":"Mandel, L. J. Metabolic substrates, cellular energy production, and the regulation of proximal tubular transport. Annu. Rev. Physiol. 47, 85\u2013101 (1985).","journal-title":"Annu. Rev. Physiol."},{"key":"1066_CR42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/1479164119827611","volume":"16","author":"CJ Nolan","year":"2019","unstructured":"Nolan, C. J. & Prentki, M. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: time for a conceptual framework shift. Diabetes Vasc. Dis. Res. 16, 118\u2013127 (2019).","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"1066_CR43","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nrneph.2018.9","volume":"145","author":"JM Forbes","year":"2018","unstructured":"Forbes, J. M. & Thorburn, D. R. Mitochondrial dysfunction in diabetic kidney disease. Nat. Rev. Nephrol. 145, 291\u2013312 (2018).","journal-title":"Nat. Rev. Nephrol."},{"key":"1066_CR44","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1210\/clinem\/dgaa364","volume":"106","author":"M Abdul-Ghani","year":"2021","unstructured":"Abdul-Ghani, M. & DeFronzo, R. A. Insulin resistance and hyperinsulinemia: the egg and the chicken. J. Clin. Endocrinol. Metab. 106, 1897\u20131899 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1066_CR45","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","volume":"6","author":"E Ahlqvist","year":"2018","unstructured":"Ahlqvist, E. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 6, 361\u2013369 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1066_CR46","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1172\/JCI113272","volume":"80","author":"P Castellino","year":"1987","unstructured":"Castellino, P., Luzi, L., Simonson, D. C., Haymond, M. & DeFronzo, R. A. Effect of insulin and plasma amino acid concentrations on leucine metabolism in man. Role of substrate availability on estimates of whole body protein synthesis. J. Clin. Invest. 80, 1784\u20131793 (1987).","journal-title":"J. Clin. Invest."},{"key":"1066_CR47","doi-asserted-by":"publisher","first-page":"C1024","DOI":"10.1152\/ajpcell.00144.2013","volume":"306","author":"MM Mariappan","year":"2014","unstructured":"Mariappan, M. M. et al. Combined acute hyperglycemic and hyperinsulinemic clamp induced profibrotic and proinflammatory responses in the kidney. Am. J. Physiol. Cell Physiol. 306, C1024\u2013C1031 (2014).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"1066_CR48","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.143619","volume":"6","author":"HJ Lee","year":"2021","unstructured":"Lee, H. J. et al. Proximal tubular epithelial insulin receptor mediates high-fat diet\u2013induced kidney injury. JCI Insight 6, e143619 (2021).","journal-title":"JCI Insight"},{"key":"1066_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/srep45522","volume":"7","author":"N Naderpoor","year":"2017","unstructured":"Naderpoor, N. et al. Higher glomerular filtration rate is related to insulin resistance but not to obesity in a predominantly obese non-diabetic cohort. Sci. Rep. 7, 45522 (2017).","journal-title":"Sci. Rep."},{"key":"1066_CR50","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2337\/dc19-1651","volume":"43","author":"EJM Van Bommel","year":"2020","unstructured":"Van Bommel, E. J. M. et al. Insulin sensitivity and renal hemodynamic function in metformin-treated adults with type 2 diabetes and preserved renal function. Diabetes Care 43, 228\u2013234 (2020).","journal-title":"Diabetes Care"},{"key":"1066_CR51","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.ekir.2023.01.001","volume":"8","author":"MJB van Baar","year":"2023","unstructured":"van Baar, M. J. B. et al. Acute effects of insulin infusion on kidney hemodynamic function in people with type 2 diabetes and normal kidney function. Kidney Int. Rep. 8, 916\u2013920 (2023).","journal-title":"Kidney Int. Rep."},{"key":"1066_CR52","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1291\/hypres.31.127","volume":"31","author":"T Fukui","year":"2008","unstructured":"Fukui, T., Hirano, T., Shiraishi, Y., Nagashima, M. & Adachi, M. Chronic insulin infusion normalizes blood pressure and the gene expressions of angiotensin II type 1 receptor in fructose-fed rats. Hypertens. Res. 31, 115\u2013121 (2008).","journal-title":"Hypertens. Res."},{"key":"1066_CR53","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nrneph.2016.145","volume":"12","author":"F Artunc","year":"2016","unstructured":"Artunc, F. et al. The impact of insulin resistance on the kidney and vasculature. Nat. Rev. Nephrol. 12, 721\u2013737 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"1066_CR54","doi-asserted-by":"publisher","first-page":"422323","DOI":"10.3389\/fendo.2018.00693","volume":"9","author":"AC Lay","year":"2018","unstructured":"Lay, A. C. & Coward, R. J. M. The evolving importance of insulin signaling in podocyte health and disease. Front. Endocrinol. 9, 422323 (2018).","journal-title":"Front. Endocrinol."},{"key":"1066_CR55","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1007\/s00125-017-4394-0","volume":"60","author":"AC Lay","year":"2017","unstructured":"Lay, A. C. et al. Prolonged exposure of mouse and human podocytes to insulin induces insulin resistance through lysosomal and proteasomal degradation of the insulin receptor. Diabetologia 60, 2299\u20132311 (2017).","journal-title":"Diabetologia"},{"key":"1066_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78376-1","volume":"10","author":"B Denhez","year":"2020","unstructured":"Denhez, B. et al. Saturated fatty acids induce insulin resistance in podocytes through inhibition of IRS1 via activation of both IKK\u03b2 and mTORC1. Sci. Rep. 10, 21628 (2020).","journal-title":"Sci. Rep."},{"key":"1066_CR57","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41418-025-01477-9","volume":"32","author":"Q Yuan","year":"2025","unstructured":"Yuan, Q. et al. PRDM16 deficiency promotes podocyte injury by impairing insulin receptor signaling. Cell Death Differ. 32, 1536\u20131554 (2025).","journal-title":"Cell Death Differ."},{"key":"1066_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26900-w","volume":"12","author":"JH Kim","year":"2021","unstructured":"Kim, J. H. et al. Insulin-activated store-operated Ca2+ entry via Orai1 induces podocyte actin remodeling and causes proteinuria. Nat. Commun. 12, 6537 (2021).","journal-title":"Nat. Commun."},{"key":"1066_CR59","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1524-6175.2004.04065.x","volume":"6","author":"GL Bakris","year":"2004","unstructured":"Bakris, G. L. Implications of albuminuria on kidney disease progression. J. Clin. Hypertens. 6, 18\u201322 (2004).","journal-title":"J. Clin. Hypertens."},{"key":"1066_CR60","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","volume":"7","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink, H. J. L. et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 7, 128\u2013139 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1066_CR61","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.2337\/dc08-2151","volume":"32","author":"T Babazono","year":"2009","unstructured":"Babazono, T. et al. Higher levels of urinary albumin excretion within the normal range predict faster decline in glomerular filtration rate in diabetic patients. Diabetes Care 32, 1518\u20131520 (2009).","journal-title":"Diabetes Care"},{"key":"1066_CR62","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2337\/diab.43.5.629","volume":"43","author":"A K\u00f6rner","year":"1994","unstructured":"K\u00f6rner, A., Ekl\u00f6f, A. C., Celsi, G. & Aperia, A. Increased renal metabolism in diabetes. Mechanism and functional implications. Diabetes 43, 629\u2013633 (1994).","journal-title":"Diabetes"},{"key":"1066_CR63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1146\/annurev.ph.48.030186.000301","volume":"48","author":"SP Soltoff","year":"1986","unstructured":"Soltoff, S. P. ATP and the regulation of renal cell function. Annu. Rev. Physiol. 48, 9\u201331 (1986).","journal-title":"Annu. Rev. Physiol."},{"key":"1066_CR64","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nrneph.2010.124","volume":"6","author":"I Mimura","year":"2010","unstructured":"Mimura, I. & Nangaku, M. The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat. Rev. Nephrol. 6, 667\u2013678 (2010).","journal-title":"Nat. Rev. Nephrol."},{"key":"1066_CR65","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8492467","volume":"2020","author":"R Pereira-Moreira","year":"2020","unstructured":"Pereira-Moreira, R. & Muscelli, E. Effect of insulin on proximal tubules handling of glucose: a systematic review. J. Diabetes Res. 2020, 8492467 (2020).","journal-title":"J. Diabetes Res."},{"key":"1066_CR66","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/jcb.25632","volume":"118","author":"G Pandey","year":"2017","unstructured":"Pandey, G. et al. Reduced insulin receptor expression enhances proximal tubule gluconeogenesis. J. Cell. Biochem. 118, 276\u2013285 (2017).","journal-title":"J. Cell. Biochem."},{"key":"1066_CR67","doi-asserted-by":"publisher","first-page":"R547","DOI":"10.1152\/ajpregu.00016.2018","volume":"315","author":"DL Irsik","year":"2018","unstructured":"Irsik, D. L. & Brands, M. W. Physiological hyperinsulinemia caused by acute hyperglycemia minimizes renal sodium loss by direct action on kidneys. Am. J. Physiol. Regul. Integr. Comp. Physiol. 315, R547\u2013R552 (2018).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"1066_CR68","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1172\/JCI110067","volume":"67","author":"RA DeFronzo","year":"1981","unstructured":"DeFronzo, R. A. et al. Insulin resistance in uremia. J. Clin. Invest. 67, 563\u2013568 (1981).","journal-title":"J. Clin. Invest."},{"key":"1066_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2019.107479","volume":"34","author":"O Milas","year":"2020","unstructured":"Milas, O. et al. Pro-inflammatory cytokines are associated with podocyte damage and proximal tubular dysfunction in the early stage of diabetic kidney disease in type 2 diabetes mellitus patients. J. Diabetes Complications 34, 107479 (2020).","journal-title":"J. Diabetes Complications"},{"key":"1066_CR70","doi-asserted-by":"publisher","DOI":"10.1172\/JCI165654","volume":"133","author":"S Mohandes","year":"2023","unstructured":"Mohandes, S. et al. Molecular pathways that drive diabetic kidney disease. J. Clin. Invest. 133, e165654 (2023).","journal-title":"J. Clin. Invest."},{"key":"1066_CR71","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3389\/fendo.2014.00169","volume":"5","author":"S Merscher","year":"2014","unstructured":"Merscher, S., Pedigo, C. E. & Mendez, A. J. Metabolism, energetics, and lipid biology in the podocyte \u2014 cellular cholesterol mediated glomerular injury. Front. Endocrinol. 5, 169 (2014).","journal-title":"Front. Endocrinol."},{"key":"1066_CR72","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1172\/JCI32057","volume":"117","author":"X Wang","year":"2007","unstructured":"Wang, X. et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J. Clin. Invest. 117, 2216\u20132224 (2007).","journal-title":"J. Clin. Invest."},{"key":"1066_CR73","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.2337\/db13-1167","volume":"62","author":"A Tufro","year":"2013","unstructured":"Tufro, A. Cholesterol accumulation in podocytes: a potential novel targetable pathway in diabetic nephropathy. Diabetes 62, 3661\u20133662 (2013).","journal-title":"Diabetes"},{"key":"1066_CR74","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1172\/JCI125316","volume":"129","author":"GM Ducasa","year":"2019","unstructured":"Ducasa, G. M. et al. ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes. J. Clin. Invest. 129, 3387\u20133400 (2019).","journal-title":"J. Clin. Invest."},{"key":"1066_CR75","doi-asserted-by":"publisher","first-page":"F1241","DOI":"10.1152\/ajprenal.00379.2019","volume":"317","author":"A Mitrofanova","year":"2019","unstructured":"Mitrofanova, A., Sosa, M. A. & Fornoni, A. Lipid mediators of insulin signaling in diabetic kidney disease. Am. J. Physiol. Renal Physiol. 317, F1241\u2013F1252 (2019).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1066_CR76","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1053\/j.ajkd.2018.06.020","volume":"72","author":"BI Freedman","year":"2018","unstructured":"Freedman, B. I., Limou, S., Ma, L. & Kopp, J. B. APOL1-associated nephropathy: a key contributor to racial disparities in CKD. Am. J. Kidney Dis. 72, S8\u2013S16 (2018).","journal-title":"Am. J. Kidney Dis."},{"key":"1066_CR77","doi-asserted-by":"publisher","first-page":"p1","DOI":"10.1159\/000151272","volume":"110","author":"J Li","year":"2008","unstructured":"Li, J., Li, H., Wen, Y. B. & Li, X. W. Very-low-density lipoprotein-induced triglyceride accumulation in human mesangial cells is mainly mediated by lipoprotein lipase. Nephron Physiol. 110, p1\u2013p10 (2008).","journal-title":"Nephron Physiol."},{"key":"1066_CR78","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1152\/ajprenal.00136.2011","volume":"302","author":"L Uttarwar","year":"2012","unstructured":"Uttarwar, L., Gao, B., Ingram, A. J. & Krepinsky, J. C. SREBP-1 activation by glucose mediates TGF-\u03b2 upregulation in mesangial cells. Am. J. Physiol. Renal Physiol. 302, 329\u2013341 (2012).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1066_CR79","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1475-2840-4-2","volume":"4","author":"R Mishra","year":"2005","unstructured":"Mishra, R. & Simonson, M. S. Saturated free fatty acids and apoptosis in microvascular mesangial cells: palmitate activates pro-apoptotic signaling involving caspase 9 and mitochondrial release of endonuclease G. Cardiovasc. Diabetol. 4, 2 (2005).","journal-title":"Cardiovasc. Diabetol."},{"key":"1066_CR80","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/ki.2010.530","volume":"79","author":"Y Tanaka","year":"2011","unstructured":"Tanaka, Y. et al. Fenofibrate, a PPAR\u03b1 agonist, has renoprotective effects in mice by enhancing renal lipolysis. Kidney Int. 79, 871\u2013882 (2011).","journal-title":"Kidney Int."},{"key":"1066_CR81","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1152\/physiol.00042.2012","volume":"28","author":"C Hagberg","year":"2013","unstructured":"Hagberg, C., Mehlem, A., Falkevall, A., Muhl, L. & Eriksson, U. Endothelial fatty acid transport: role of vascular endothelial growth factor B. Physiology 28, 125\u2013134 (2013).","journal-title":"Physiology"},{"key":"1066_CR82","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMcibr1005397","volume":"363","author":"DM Muoio","year":"2010","unstructured":"Muoio, D. M. Metabolism and vascular fatty acid transport. N. Engl. J. Med. 363, 291\u2013293 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1066_CR83","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1161\/CIRCRESAHA.114.305641","volume":"115","author":"I Zeller","year":"2014","unstructured":"Zeller, I. & Srivastava, S. Macrophage functions in atherosclerosis. Circ. Res. 115, e83\u2013e85 (2014).","journal-title":"Circ. Res."},{"key":"1066_CR84","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fcvm.2020.00010","volume":"7","author":"JE Kanter","year":"2020","unstructured":"Kanter, J. E., Hsu, C. C. & Bornfeldt, K. E. Monocytes and macrophages as protagonists in vascular complications of diabetes. Front. Cardiovasc. Med. 7, 10 (2020).","journal-title":"Front. Cardiovasc. Med."},{"key":"1066_CR85","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.jaac.2010.05.017","volume":"49","author":"KR Merikangas","year":"2010","unstructured":"Merikangas, K. R. et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the national comorbidity survey replication-adolescent supplement (NCS-A). J. Am. Acad. Child. Adolesc. Psychiatry 49, 980\u2013989 (2010).","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"1066_CR86","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1152\/ajprenal.00484.2013","volume":"306","author":"C Ruggiero","year":"2014","unstructured":"Ruggiero, C. et al. Albumin-bound fatty acids but not albumin itself alter redox balance in tubular epithelial cells and induce a peroxide-mediated redox-sensitive apoptosis. Am. J. Physiol. Renal Physiol. 306, 896\u2013906 (2014).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1066_CR87","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/ars.2012.4603","volume":"18","author":"W Cao","year":"2013","unstructured":"Cao, W. et al. Advanced oxidation protein products activate intrarenal renin-angiotensin system via a CD36-mediated, redox-dependent pathway. Antioxid. Redox Signal. 18, 19\u201335 (2013).","journal-title":"Antioxid. Redox Signal."},{"key":"1066_CR88","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-023-05078-y","volume":"81","author":"Y Hou","year":"2024","unstructured":"Hou, Y. et al. Mitochondrial oxidative damage reprograms lipid metabolism of renal tubular epithelial cells in the diabetic kidney. Cell. Mol. Life Sci. 81, 23 (2024).","journal-title":"Cell. Mol. Life Sci."},{"key":"1066_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2014.00186","volume":"5","author":"J Sieber","year":"2014","unstructured":"Sieber, J. & Jehle, A. W. Free fatty acids and their metabolism affect function and survival of podocytes. Front. Endocrinol. 5, 186 (2014).","journal-title":"Front. Endocrinol."},{"key":"1066_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17111868","volume":"17","author":"T Iwai","year":"2016","unstructured":"Iwai, T. et al. Stearoyl-coA desaturase-1 protects cells against lipotoxicity-mediated apoptosis in proximal tubular cells. Int. J. Mol. Sci. 17, 1868 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"1066_CR91","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.kint.2018.09.023","volume":"95","author":"TM Jao","year":"2019","unstructured":"Jao, T. M. et al. ATF6\u03b1 downregulation of PPAR\u03b1 promotes lipotoxicity-induced tubulointerstitial fibrosis. Kidney Int. 95, 577\u2013589 (2019).","journal-title":"Kidney Int."},{"key":"1066_CR92","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1681\/ASN.2017030350","volume":"29","author":"F Afshinnia","year":"2018","unstructured":"Afshinnia, F. et al. Impaired B-oxidation and altered complex lipid fatty acid partitioning with advancing CKD. J. Am. Soc. Nephrol. 29, 295\u2013306 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1066_CR93","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fmed.2020.00065","volume":"7","author":"HS Jang","year":"2020","unstructured":"Jang, H. S., Noh, M. R., Kim, J. & Padanilam, B. J. Defective mitochondrial fatty acid oxidation and lipotoxicity in kidney diseases. Front. Med. 7, 65 (2020).","journal-title":"Front. Med."},{"key":"1066_CR94","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1152\/ajprenal.00697.2013","volume":"306","author":"S Liu","year":"2014","unstructured":"Liu, S., Soong, Y., Seshan, S. V. & Szeto, H. H. Novel cardiolipin therapeutic protects endothelial mitochondria during renal ischemia and mitigates microvascular rarefaction, inflammation, and fibrosis. Am. J. Physiol. Renal Physiol. 306, 970\u2013980 (2014).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1066_CR95","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/15548627.2017.1283084","volume":"13","author":"Y Takabatake","year":"2017","unstructured":"Takabatake, Y., Yamamoto, T. & Isaka, Y. Stagnation of autophagy: a novel mechanism of renal lipotoxicity. Autophagy 13, 775\u2013776 (2017).","journal-title":"Autophagy"},{"key":"1066_CR96","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/nrneph.2017.107","volume":"13","author":"P Bhargava","year":"2017","unstructured":"Bhargava, P. & Schnellmann, R. G. Mitochondrial energetics in the kidney. Nat. Rev. Nephrol. 13, 629\u2013646 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"1066_CR97","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.semnephrol.2018.01.002","volume":"38","author":"G Zhang","year":"2018","unstructured":"Zhang, G., Darshi, M. & Sharma, K. The Warburg effect in diabetic kidney disease. Semin. Nephrol. 38, 111\u2013120 (2018).","journal-title":"Semin. Nephrol."},{"key":"1066_CR98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120632","volume":"10","author":"Y Guo","year":"2015","unstructured":"Guo, Y. et al. Shift work and the relationship with metabolic syndrome in Chinese aged workers. PLoS ONE 10, e0120632 (2015).","journal-title":"PLoS ONE"},{"key":"1066_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/nu11071664","volume":"11","author":"H Nishi","year":"2019","unstructured":"Nishi, H., Higashihara, T. & Inagi, R. Lipotoxicity in kidney, heart, and skeletal muscle dysfunction. Nutrients 11, 1664 (2019).","journal-title":"Nutrients"},{"key":"1066_CR100","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/j.1463-1326.2004.00439.x","volume":"7","author":"M Krebs","year":"2005","unstructured":"Krebs, M. & Roden, M. Molecular mechanisms of lipid-induced insulin resistance in muscle, liver and vasculature. Diabetes, Obes. Metab. 7, 621\u2013632 (2005).","journal-title":"Diabetes, Obes. Metab."},{"key":"1066_CR101","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/978-3-031-63657-8_14","volume":"1460","author":"D Yaz\u0131c\u0131","year":"2024","unstructured":"Yaz\u0131c\u0131, D., Demir, S. \u00c7 & Sezer, H. Insulin resistance, obesity, and lipotoxicity. Adv. Exp. Med. Biol. 1460, 391\u2013430 (2024).","journal-title":"Adv. Exp. Med. Biol."},{"key":"1066_CR102","doi-asserted-by":"publisher","first-page":"E87","DOI":"10.1152\/ajpendo.1991.261.1.E87","volume":"261","author":"JE Friedman","year":"1991","unstructured":"Friedman, J. E. et al. Muscle insulin resistance in uremic humans: glucose transport, glucose transporters, and insulin receptors. Am. J. Physiol. Endocrinol. Metab. 261, E87\u2013E94 (1991).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1066_CR103","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1681\/ASN.2004090742","volume":"16","author":"B Becker","year":"2005","unstructured":"Becker, B. et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J. Am. Soc. Nephrol. 16, 1091\u20131098 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1066_CR104","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1046\/j.1523-1755.1998.00898.x","volume":"53","author":"D Fliser","year":"1998","unstructured":"Fliser, D. et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int. 53, 1343\u20131347 (1998).","journal-title":"Kidney Int."},{"key":"1066_CR105","doi-asserted-by":"publisher","first-page":"F1087","DOI":"10.1152\/ajprenal.00340.2016","volume":"311","author":"B Spoto","year":"2016","unstructured":"Spoto, B., Pisano, A. & Zoccali, C. Insulin resistance in chronic kidney disease: a systematic review. Am. J. Physiol. Renal Physiol. 311, F1087\u2013F1108 (2016).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1066_CR106","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1681\/ASN.2004100842","volume":"17","author":"JL Bailey","year":"2006","unstructured":"Bailey, J. L., Zheng, B., Hu, Z., Price, S. R. & Mitch, W. E. Chronic kidney disease causes defects in signaling through the insulin receptor substrate\/phosphatidylinositol 3-kinase\/Akt pathway: Implications for muscle atrophy. J. Am. Soc. Nephrol. 17, 1388\u20131394 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1066_CR107","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/01.ASN.0000046029.53933.09","volume":"14","author":"J Chen","year":"2003","unstructured":"Chen, J. et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J. Am. Soc. Nephrol. 14, 469\u2013477 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1066_CR108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193473","volume":"13","author":"C Wang","year":"2018","unstructured":"Wang, C. et al. GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis. PLoS ONE 13, e0193473 (2018).","journal-title":"PLoS ONE"},{"key":"1066_CR109","volume":"10","author":"JS Teodoro","year":"2019","unstructured":"Teodoro, J. S., Nunes, S., Rolo, A. P., Reis, F. & Palmeira, C. M. Therapeutic options targeting oxidative stress, mitochondrial dysfunction and inflammation to hinder the progression of vascular complications of diabetes. Front. Physiol. 10, 387172 (2019).","journal-title":"Front. Physiol."},{"key":"1066_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114465","volume":"161","author":"L Ren","year":"2023","unstructured":"Ren, L. et al. The role of lipotoxicity in kidney disease: from molecular mechanisms to therapeutic prospects. Biomed. Pharmacother. 161, 114465 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"1066_CR111","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1210\/jc.2019-00004","volume":"104","author":"A Asmar","year":"2019","unstructured":"Asmar, A. et al. Extracellular fluid volume expansion uncovers a natriuretic action of GLP-1: a functional GLP-1-renal axis in man. J. Clin. Endocrinol. Metab. 104, 2509\u20132519 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1066_CR112","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","volume":"105","author":"KC Sourris","year":"2024","unstructured":"Sourris, K. C. et al. Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products\u2013induced inflammation. Kidney Int. 105, 132\u2013149 (2024).","journal-title":"Kidney Int."},{"key":"1066_CR113","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/ki.2013.427","volume":"85","author":"H Fujita","year":"2014","unstructured":"Fujita, H. et al. The protective roles of GLP-1R signaling in diabetic nephropathy: Possible mechanism and therapeutic potential. Kidney Int. 85, 579\u2013589 (2014).","journal-title":"Kidney Int."},{"key":"1066_CR114","doi-asserted-by":"publisher","first-page":"E1019","DOI":"10.1152\/ajpendo.00195.2019","volume":"319","author":"S Yang","year":"2020","unstructured":"Yang, S. et al. Glucagon-like peptide-1 alleviates diabetic kidney disease through activation of autophagy by regulating AMP-activated protein kinase-mammalian target of rapamycin pathway. Am. J. Physiol. Endocrinol. Metab. 319, E1019\u2013E1030 (2020).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1066_CR115","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1093\/ckj\/sfac069","volume":"15","author":"A Granata","year":"2022","unstructured":"Granata, A. et al. GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art. Clin. Kidney J. 15, 1657\u20131665 (2022).","journal-title":"Clin. Kidney J."},{"key":"1066_CR116","doi-asserted-by":"publisher","first-page":"E747","DOI":"10.1152\/ajpendo.00374.2023","volume":"326","author":"BE McFarlin","year":"2024","unstructured":"McFarlin, B. E., Duffin, K. L. & Konkar, A. Incretin and glucagon receptor polypharmacology in chronic kidney disease. Am. J. Physiol. - Endocrinol. Metab. 326, E747\u2013E766 (2024).","journal-title":"Am. J. Physiol. - Endocrinol. Metab."},{"key":"1066_CR117","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrneph.2016.170","volume":"13","author":"RA DeFronzo","year":"2017","unstructured":"DeFronzo, R. A., Norton, L. & Abdul-Ghani, M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev. Nephrol. 13, 11\u201326 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"1066_CR118","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","volume":"175","author":"RA DeFronzo","year":"2021","unstructured":"DeFronzo, R. A., Reeves, W. B. & Awad, A. S. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat. Rev. Nephrol. 175, 319\u2013334 (2021).","journal-title":"Nat. Rev. Nephrol."},{"key":"1066_CR119","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.kint.2024.03.019","volume":"105","author":"K Yau","year":"2024","unstructured":"Yau, K., Cherney, D. Z. I., van Raalte, D. H. & Wever, B. E. Kidney protective mechanisms of SGLT2 inhibitors: evidence for a hemodynamic effect. Kidney Int. 105, 1168\u20131172 (2024).","journal-title":"Kidney Int."},{"key":"1066_CR120","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","volume":"44","author":"F Bonnet","year":"2018","unstructured":"Bonnet, F. & Scheen, A. J. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab. 44, 457\u2013464 (2018).","journal-title":"Diabetes Metab."},{"key":"1066_CR121","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.2337\/dc13-0387","volume":"36","author":"RA Defronzo","year":"2013","unstructured":"Defronzo, R. A. et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 36, 3169\u20133176 (2013).","journal-title":"Diabetes Care"},{"key":"1066_CR122","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1210\/jc.2017-01838","volume":"103","author":"H Al Jobori","year":"2018","unstructured":"Al Jobori, H. et al. Empagliflozin treatment is associated with improved \u03b2-cell function in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 103, 1402\u20131407 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1066_CR123","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1002\/j.2040-4603.2022.tb00207.x","volume":"12","author":"V Vallon","year":"2022","unstructured":"Vallon, V. & Nakagawa, T. Renal tubular handling of glucose and fructose in health and disease. Compr. Physiol. 12, 2995\u20133044 (2022).","journal-title":"Compr. Physiol."},{"key":"1066_CR124","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1152\/ajpregu.00357.2011","volume":"302","author":"SC Thomson","year":"2012","unstructured":"Thomson, S. C. et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302, 75\u201383 (2012).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"1066_CR125","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00125-008-1256-9","volume":"52","author":"DK Coletta","year":"2009","unstructured":"Coletta, D. K. et al. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial. Diabetologia 52, 723\u2013732 (2009).","journal-title":"Diabetologia"},{"key":"1066_CR126","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.18364","volume":"28","author":"Z Fang","year":"2024","unstructured":"Fang, Z., Liu, R., Xie, J. & He, J. C. Molecular mechanism of renal lipid accumulation in diabetic kidney disease. J. Cell. Mol. Med. 28, e18364 (2024).","journal-title":"J. Cell. Mol. Med."},{"key":"1066_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2022.100176","volume":"63","author":"K Wallenius","year":"2022","unstructured":"Wallenius, K. et al. The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic \u03b2-oxidation, and induces ketosis. J. Lipid Res. 63, 100176 (2022).","journal-title":"J. Lipid Res."},{"key":"1066_CR128","doi-asserted-by":"publisher","DOI":"10.1111\/nep.70098","volume":"30","author":"S Anumas","year":"2025","unstructured":"Anumas, S. & Inagi, R. Mitigating Lipotoxicity: a potential mechanism to delay chronic kidney disease progression using current pharmacological therapies. Nephrology 30, e70098 (2025).","journal-title":"Nephrology"},{"key":"1066_CR129","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/jdi.12802","volume":"9","author":"S Takagi","year":"2018","unstructured":"Takagi, S. et al. Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet. J. Diabetes Investig. 9, 1025\u20131032 (2018).","journal-title":"J. Diabetes Investig."},{"key":"1066_CR130","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/dom.14018","volume":"22","author":"S Mulder","year":"2020","unstructured":"Mulder, S. et al. A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes. Diabetes, Obes. Metab. 22, 1157\u20131166 (2020).","journal-title":"Diabetes, Obes. Metab."},{"key":"1066_CR131","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s43440-022-00442-4","volume":"75","author":"B Afsar","year":"2023","unstructured":"Afsar, B. & Afsar, R. E. Sodium\u2013glucose cotransporter inhibitors and kidney fibrosis: review of the current evidence and related mechanisms. Pharmacol. Rep. 75, 44\u201368 (2023).","journal-title":"Pharmacol. Rep."},{"key":"1066_CR132","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1053\/j.ajkd.2020.04.016","volume":"77","author":"M Packer","year":"2021","unstructured":"Packer, M. Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics. Am. J. Kidney Dis. 77, 280\u2013286 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"1066_CR133","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000000000425","volume":"5","author":"A Upadhyay","year":"2024","unstructured":"Upadhyay, A. SGLT2 Inhibitors and kidney protection: mechanisms beyond tubuloglomerular feedback. Kidney360 5, 771 (2024).","journal-title":"Kidney360"},{"key":"1066_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100895","volume":"37","author":"JC Laursen","year":"2021","unstructured":"Laursen, J. C. et al. Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: a randomised, double-blind, placebo-controlled crossover trial. EClinicalMedicine 37, 100895 (2021).","journal-title":"EClinicalMedicine"},{"key":"1066_CR135","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cmet.2020.06.020","volume":"32","author":"I Tomita","year":"2020","unstructured":"Tomita, I. et al. SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab. 32, 404\u2013419.e6 (2020).","journal-title":"Cell Metab."},{"key":"1066_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2024.02.003","volume":"35","author":"M Mashayekhi","year":"2024","unstructured":"Mashayekhi, M., Safa, B. I., Gonzalez, M. S. C., Kim, S. F. & Echouffo-Tcheugui, J. B. Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors. Trends Endocrinol. Metab. 35, 425 (2024).","journal-title":"Trends Endocrinol. Metab."},{"key":"1066_CR137","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1111\/j.1463-1326.2008.00880.x","volume":"10","author":"Y Miyazaki","year":"2008","unstructured":"Miyazaki, Y. & Defronzo, R. A. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes, Obes. Metab. 10, 1204\u20131211 (2008).","journal-title":"Diabetes, Obes. Metab."},{"key":"1066_CR138","doi-asserted-by":"publisher","first-page":"18745","DOI":"10.1073\/pnas.0903032106","volume":"106","author":"DD Sears","year":"2009","unstructured":"Sears, D. D. et al. Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization. Proc. Natl. Acad. Sci. USA. 106, 18745\u201318750 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"1066_CR139","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1530\/eje.1.02134","volume":"154","author":"P Iglesias","year":"2006","unstructured":"Iglesias, P. & Di\u00e9z, J. J. Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur. J. Endocrinol. 154, 613\u2013621 (2006).","journal-title":"Eur. J. Endocrinol."},{"key":"1066_CR140","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1053\/j.ajkd.2009.11.013","volume":"55","author":"PA Sarafidis","year":"2010","unstructured":"Sarafidis, P. A., Stafylas, P. C., Georgianos, P. I., Saratzis, A. N. & Lasaridis, A. N. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am. J. Kidney Dis. 55, 835\u2013847 (2010).","journal-title":"Am. J. Kidney Dis."},{"key":"1066_CR141","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.2337\/dc20-1584","volume":"43","author":"CL Yen","year":"2020","unstructured":"Yen, C. L. et al. Pioglitazone reduces mortality and adverse events in patients with type 2 diabetes and with advanced chronic kidney disease: National Cohort Study. Diabetes Care 43, e152\u2013e153 (2020).","journal-title":"Diabetes Care"},{"key":"1066_CR142","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00125-007-0698-9","volume":"50","author":"M Bajaj","year":"2007","unstructured":"Bajaj, M. et al. Effects of peroxisome proliferator-activated receptor (PPAR)-\u03b1 and PPAR-\u03b3 agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 50, 1723\u20131731 (2007).","journal-title":"Diabetologia"},{"key":"1066_CR143","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1007\/s001250100031","volume":"44","author":"Y Miyazaki","year":"2001","unstructured":"Miyazaki, Y. et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 44, 2210\u20132219 (2001).","journal-title":"Diabetologia"},{"key":"1066_CR144","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","volume":"364","author":"RA DeFronzo","year":"2011","unstructured":"DeFronzo, R. A. et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N. Engl. J. Med. 364, 1104\u20131115 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1066_CR145","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","volume":"368","author":"HC Gerstein","year":"2006","unstructured":"Gerstein, H. C. et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368, 1096\u20131105 (2006).","journal-title":"Lancet"},{"key":"1066_CR146","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2337\/dc07-1868","volume":"31","author":"GR Dagenais","year":"2008","unstructured":"Dagenais, G. R. et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 31, 1007\u20131014 (2008).","journal-title":"Diabetes Care"},{"key":"1066_CR147","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13649","volume":"25","author":"FG Scurt","year":"2024","unstructured":"Scurt, F. G. et al. Association of metabolic syndrome and chronic kidney disease. Obes. Rev. 25, e13649 (2024).","journal-title":"Obes. Rev."},{"key":"1066_CR148","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele, C. E. et al. Cardiovascular-Kidney-Metabolic Health: a presidential advisory from the American Heart Association. Circulation 148, 1606\u20131635 (2023).","journal-title":"Circulation"},{"key":"1066_CR149","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"KDIGO CKD Work Group","year":"2024","unstructured":"KDIGO CKD Work Group KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 105, S117\u2013S314 (2024).","journal-title":"Kidney Int."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01066-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01066-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01066-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:02:25Z","timestamp":1782129745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01066-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":149,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1066"],"URL":"https:\/\/doi.org\/10.1038\/s41581-026-01066-0","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"27 February 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.A.D. is a member of the Speakers Bureau for AstraZeneca, CORCEPT, a member of the Advisory Board of Astra Zeneca, Novo Nordisk, Aardvark, Renalytix, CORCEPT, Alnylam, 89Bio and Regeneron, and has received research grants from AstraZeneca, 89Bio, Amgen, Medality and Eli Lilly. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}